

# PATIENT BROCHURE


The information in this brochure is provided for informational purposes only to help healthcare professionals explain this diagnostic test to patients. Patients should consult their oncologist for an individual medical assessment and to determine whether this test is appropriate for them.



The answers your oncologist needs for a personalised treatment approach - with a simple blood draw.

---

GUARDANT 360<sup>®</sup> CDx



**Guardant360® CDx** is a blood test that helps your doctor select a personalised treatment approach.



Results in approximately **5 days TAT\*** from receipt of the sample at the laboratory.

**Your physician will be notified once the results are ready.**

\* TAT = Turnaround Time



Contact Client Services  
+44 (0) 808 189 5057  
[international@guardanthealth.com](mailto:international@guardanthealth.com)

## IDENTIFYING TREATMENT OPTIONS

For patients with metastatic cancer, personalised therapies may offer promising new treatment options. However, a comprehensive genomic profile is needed so that your oncologist can identify the most appropriate therapeutic options.

The Guardant360® CDx liquid biopsy test may provide this information through a simple blood draw, without the need for tissue sampling.

## A COMPREHENSIVE VIEW

Guardant360® CDx is a blood test that captures and analyses tumour-derived DNA circulating in the bloodstream.\* This provides a comprehensive overview of mutations and alterations present across both primary and metastatic tumour sites.

Following analysis, a report is issued outlining the genomic alterations detected in the blood. The report lists therapies associated with those alterations and available clinical trials.\*\* Your oncologist will interpret your results to identify the most appropriate treatment option for you.

\* Not all tumours shed DNA into the bloodstream; however, in approximately 90% of cancer types, tumours release detectable DNA.<sup>1</sup>

\*\* Not all genomic alterations have an associated therapy or clinical trial.

1. Zill OA, Banks KC, Fairclough SR, et al. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. *Clinical Cancer Research*. 2018.

## HOW IT WORKS



BLOOD COLLECTION

DAY 1



Blood sample received at the laboratory



Sample processing begins

Our Client Services Team will contact you or the clinic regarding payment

DAY 5




Guardant360® CDx report sent to your oncologist

Guardant360® CDx identifies alterations in tumour DNA circulating in the blood

Your oncologist reviews the Guardant360® CDx results



# A targeted therapy can make a difference



## Guardant360<sup>®</sup> CDx

Guardant360<sup>®</sup> CDx analyses more than 70 clinically relevant genes to identify genomic alterations within tumour DNA and is compliant with the IVDR regulation.

- Some genomic alterations may indicate a potential response to specific therapies.
- Others may suggest possible resistance to certain treatments.

Knowing which alterations are present in your tumour helps your oncologist choose the most appropriate treatment for you.

## Your doctor may order Guardant360<sup>®</sup> CDx when:

- You are newly diagnosed with metastatic cancer
- Tissue biopsy results are incomplete or inconclusive
- At disease progression

Your doctor can order a  
**Guardant360® CDx test kit**

by clicking **Order Now**  
on our website [guardanthealth.eu](https://guardanthealth.eu).

**They can also:**



View the genes included in  
the Guardant360® CDx test



Review peer-reviewed publications  
demonstrating the performance  
and accuracy of Guardant360® CDx



Understand when Guardant360® CDx  
may be indicated



Access additional resources

GUARDANT **360**® CDx

Contact Client Services

+44 (0) 808 189 5057  
[international@guardanthealth.com](mailto:international@guardanthealth.com)  
[guardanthealth.eu](https://guardanthealth.eu)

REC-MKT-EUAA-00006-R4  
19.02.2026